UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer

Cancer medicine (Malden, MA), 2020-04, Vol.9 (7), p.2390-2402

2020

Link zum Volltext

Verfügbarkeit prüfen

Modifying factors of PD‐L1 expression on tumor cells in advanced non‐small‐cell lung cancer

Thoracic cancer, 2022-12, Vol.13 (23), p.3362-3373

2022

Link zum Volltext

Verfügbarkeit prüfen

Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status

Thoracic cancer, 2020-04, Vol.11 (4), p.1026-1037

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors

Journal of Immunology Research, 2021, Vol.2021, p.6632249-9

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of alectinib in combination with bevacizumab as first-line treatment in advanced NSCLC with confirmed ALK fusion: ALEK-B trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9074-9074

2022

Link zum Volltext

Verfügbarkeit prüfen

PP.01 Study Evaluating Alectinib Pharmacokinetics in the Hispanic Population With Advanced ALK-Rearranged Non-small-Cell Lung Cancer

Journal of thoracic oncology, 2023-03, Vol.18 (3), p.S8-S9

2023

Link zum Volltext

Verfügbarkeit prüfen

Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC

Journal of thoracic oncology, 2024-01, Vol.19 (1), p.119-129

2024

Link zum Volltext

Verfügbarkeit prüfen

A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population

Lung cancer (Amsterdam, Netherlands), 2022-12, Vol.174, p.133-140

2022

Link zum Volltext

Verfügbarkeit prüfen

Nitroglycerin (NTG) plus whole intracranial radiotherapy for brain metastases (BM) in non-small cell cancer patient (NSCLC): A randomized open label, phase II clinical trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9114-9114

2021

Link zum Volltext

Verfügbarkeit prüfen

Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort

Oncology, 2021-07, Vol.99 (8), p.539-546

2021

Link zum Volltext

Verfügbarkeit prüfen

Combination of metformin plus TKI vs. TKI alone in EGFR(+) LUNG adenocarcinoma: A randomized phase II study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9013-9013

2018

Link zum Volltext

Verfügbarkeit prüfen

Response Assessment of 68Ga-DOTA-E-[c(RGDfK)]2 PET/CT in Lung Adenocarcinoma Patients Treated with Nintedanib Plus Docetaxel

The Journal of nuclear medicine (1978), 2018-03, Vol.59 (3), p.403-409

2018

Link zum Volltext

Verfügbarkeit prüfen

Response Assessment of 68 Ga-DOTA-E-[c(RGDfK)] 2 PET/CT in Lung Adenocarcinoma Patients Treated with Nintedanib Plus Docetaxel

Journal of Nuclear Medicine, 2018-03, Vol.59 (3), p.403-409

2018

Link zum Volltext

Verfügbarkeit prüfen

Response Assessment of ^sup 68^Ga-DOTA-E-[c(RGDfK)]^sup 2^ PET/CT in Lung Adenocarcinoma Patients Treated with Nintedanib Plus Docetaxel

The Journal of nuclear medicine (1978), 2018-03, Vol.59 (3), p.403

2018

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non-Small Cell Lung Cancer

American journal of clinical oncology, 2017-12, Vol.40 (6), p.631-638

2017

Link zum Volltext

Verfügbarkeit prüfen

Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells

Pathology oncology research, 2021-04, Vol.27, p.597499-597499

2021

Link zum Volltext

Verfügbarkeit prüfen

P2.03b-083 Soluble Angiogenic Factors as Predictive Biomarkers of Response to Docetaxel plus Nintedanib as Second Line Therapy in NSCLC

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S986

2017

Link zum Volltext

Verfügbarkeit prüfen

P2.03b-083 Soluble Angiogenic Factors as Predictive Biomarkers of Response to Docetaxel plus Nintedanib as Second Line Therapy in NSCLC: Topic: Biomarkers

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S986-S986

2017

Link zum Volltext

Verfügbarkeit prüfen

P2.03b-088 PET-CT with 68Ga-RGD as Biomarker of Response to Nintedanib plus Docetaxel as Second Line Therapy in NSCLC: Topic: Biomarkers

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S989-S990

2017

Link zum Volltext

Verfügbarkeit prüfen

P2.03b-088 PET-CT with 68Ga-RGD as Biomarker of Response to Nintedanib plus Docetaxel as Second Line Therapy in NSCLC

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S989-S990

2017

Link zum Volltext

Verfügbarkeit prüfen

Células madre mesenquimales y su relación con el cáncer de pulmón

Revista americana de medicina respiratoria, 2015-09, Vol.15 (3), p.216-224

2015

Link zum Volltext

Verfügbarkeit prüfen

Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial

Targeted oncology, 2016-10, Vol.11 (5), p.619-629

2016

Link zum Volltext

Verfügbarkeit prüfen

Personalized treatment in non-small cell lung cancer

Revista de investigacion clinica, 2012-07, Vol.64 (4), p.377-386

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Humans
(11)
Oncology
(10)
Female
(8)
Middle Aged
(8)
Lung Cancer
(7)
Male
(7)
Lung Neoplasms - Drug Therapy
(6)
Adenocarcinoma Of Lung - Genetics
(5)
Lung Neoplasms - Genetics
(5)
Tumors
(5)
Aged
(4)
Biomarkers, Tumor - Genetics
(4)
Biomarkers, Tumor - Metabolism
(4)
Cancer Therapies
(4)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(4)
Carcinoma, Non-Small-Cell Lung - Pathology
(4)
Immunohistochemistry
(4)
Lung Neoplasms - Pathology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer

Modifying factors of PD‐L1 expression on tumor cells in advanced non‐small‐cell lung cancer

Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status

Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors

A phase II study of alectinib in combination with bevacizumab as first-line treatment in advanced NSCLC with confirmed ALK fusion: ALEK-B trial

PP.01 Study Evaluating Alectinib Pharmacokinetics in the Hispanic Population With Advanced ALK-Rearranged Non-small-Cell Lung Cancer

Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC

A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population

Nitroglycerin (NTG) plus whole intracranial radiotherapy for brain metastases (BM) in non-small cell cancer patient (NSCLC): A randomized open label, phase II clinical trial

Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort

Combination of metformin plus TKI vs. TKI alone in EGFR(+) LUNG adenocarcinoma: A randomized phase II study

Molecular Epidemiology of ALK Rearrangements in Advanced Lung Adenocarcinoma in Latin America

Response Assessment of 68Ga-DOTA-E-[c(RGDfK)]2 PET/CT in Lung Adenocarcinoma Patients Treated with Nintedanib Plus Docetaxel

Response Assessment of 68 Ga-DOTA-E-[c(RGDfK)] 2 PET/CT in Lung Adenocarcinoma Patients Treated with Nintedanib Plus Docetaxel

Response Assessment of ^sup 68^Ga-DOTA-E-[c(RGDfK)]^sup 2^ PET/CT in Lung Adenocarcinoma Patients Treated with Nintedanib Plus Docetaxel

Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non-Small Cell Lung Cancer

Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells

P2.03b-083 Soluble Angiogenic Factors as Predictive Biomarkers of Response to Docetaxel plus Nintedanib as Second Line Therapy in NSCLC

P2.03b-083 Soluble Angiogenic Factors as Predictive Biomarkers of Response to Docetaxel plus Nintedanib as Second Line Therapy in NSCLC: Topic: Biomarkers

P2.03b-088 PET-CT with 68Ga-RGD as Biomarker of Response to Nintedanib plus Docetaxel as Second Line Therapy in NSCLC: Topic: Biomarkers

P2.03b-088 PET-CT with 68Ga-RGD as Biomarker of Response to Nintedanib plus Docetaxel as Second Line Therapy in NSCLC

Células madre mesenquimales y su relación con el cáncer de pulmón

Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial

Personalized treatment in non-small cell lung cancer

Suchergebnisse filtern